Clinical Investigation to Assess Safety and Performance of Dermal Filler of Hyaluronic Acid

The primary endpoint is to assess the safety of dermal filler of hyaluronic acid by occurrence of Treatment-Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs) through 2 months post-treatment. Furthermore, the performance of the device will also be assessed as the aesthetical outcome measured by the Global Aesthetic Improvement Scale (GAIS), Wrinkle Severity Rating Scale (WSRS), and 2D images of subjects' faces at 2 months post-treatment.The secondary endpoints are the following:

Secondary Safety Endpoint

• To assess the safety of dermal filler of hyaluronic acid by occurrence of Treatment-related Adverse Events (TRAEs) and Serious Adverse Events (SAEs) through 6-, 9-, and 12-months post-treatment.
• To assess the safety of dermal filler of hyaluronic acid by occurrence of all AEs through 2-, 6-, 9-, and 12-months post-treatment.

Secondary Performance Endpoint

• To evaluate the performance of dermal filler of hyaluronic acid at 6-, 9- and 12-months post-treatment, assessed as the aesthetical outcome measured by the Global Aesthetic Improvement Scale (GAIS)
• Assessment of dermal filler of hyaluronic acid performance of mesofiller® Lift at 6-, 9- and 12-months post-treatment using the Wrinkle Severity Rating Scale (WSRS)
• Assessment of dermal filler of hyaluronic acid performance of dermal filler of hyaluronic acid at 6-, 9- and 12-months post-treatment using 2D images of subjects' faces
• Assessment of dermal filler of hyaluronic acid performance of dermal filler of hyaluronic acidt at 6-, 9- and 12-months post-treatment through satisfaction surveys related to the subject's appearance.

Inclusion criteria

• Subject who had provided written informed consent form.
• Adult male or female subjects between 45 and 70 years old.
• Subject with moderate (2) or higher score in the Wrinkle Severity Rating Scale (WSRS) in the lower two thirds, and in at least one of the two sides of the face, assessed at baseline by the treating investigator.
• Subject must be willing to abstain from any other facial invasive treatment (plastic surgery, implants, peelings) in the lower two thirds of the face during the clinical investigation period.

Exclusion criteria

• History of severe or multiple allergies, including allergy or hypersensitivity to injectable hyaluronic acid gel, lidocaine, anesthetics, or nerve-blocking agents or any of the components of product.
• Any disease at baseline that results in changes of facial contour or facial edema.
• Active skin disease or inflammation on or near the injection area at baseline that could interfere with the clinical investigation injections or assessments.
• History of connective tissue diseases.
• Soft tissue augmentation in the previous 6 months with bovine collagen, in the previous 12 months with porcine or human collagen, or in the previous 18 months with hyaluronic acid or hydroxyapatite.
• Any aesthetic treatment/procedure on the face in the previous 6 months that may interfere with study injections and/or study assessments.
• Subjects who have received permanent facial implants within the previous 36 months.
• Presence of any condition, which in the opinion of the investigator, made the subject unable to complete the clinical investigation per protocol.
• Subjects who are currently participating in another clinical investigation which may interfere with this clinical investigation.
• Pregnant or nursing subjects, and subjects who plan pregnancy during the clinical investigation period.
• Subjects undergoing restrictive nutritional regimens.
• Subjects who practice facial impact sports, such as boxing, karate, taekwondo and other similar sports.